0216 GMT - Pro Medicus is initiated with an overweight rating at Morgan Stanley, where analysts compare the imaging-tech provider favorably with logistics-software developer WiseTech. MS analysts write in a note that Pro Medicus's solutions, like those at WiseTech, are very scalable. Both companies' penetration of global markets is relatively low and customer churn rates are small, they observe. The MS analysts forecast Pro Medicus's customer volumes to grow by about 7% annually over the next five years, compared with overall industry growth of 2.3%. MS places a A$300 target price on the stock, which is up 1.6% at A$254.66. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
December 16, 2024 21:16 ET (02:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。